此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Young Children With Functional Constipation: a Prospective Comparative Study (BC-LGG-FC)

2026年11月16日 更新者:Biruni University

Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Children Aged 12-48 Months With Functional Constipation: A Prospective, Open-Label, Three-Arm Comparative Study

This prospective study compared Bacillus clausii and Lactobacillus rhamnosus GG, each added to dietary management, with dietary management alone in children aged 12-48 months with functional constipation (Rome IV). Children assigned to probiotic treatment were randomly allocated to Bacillus clausii or Lactobacillus rhamnosus GG (2 × 10⁹ spores or CFU daily for two months); consecutive children receiving dietary management alone served as controls. Defecation frequency, stool consistency, painful defecation and abdominal distension were assessed at baseline and at months 1 and 2.

研究概览

详细说明

This prospective, open-label, three-arm comparative study was conducted at the pediatric gastroenterology outpatient clinic of Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Türkiye, between February 2020 and July 2021.

Allocation: Children assigned to probiotic treatment were randomly allocated in a 1:1 ratio to the Bacillus clausii (BC) or Lactobacillus rhamnosus GG (LGG) group according to a computer-generated randomization list. The control group consisted of consecutive eligible children who presented during the same period and received dietary management alone; this group was not part of the randomization. No placebo was used, and caregivers and investigators were aware of group assignment.

Interventions: Children in the BC group received an oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial (Enterogermina®, Sanofi S.p.A., Italy), one vial once daily. Children in the LGG group received oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops (Maflor®, Mamsel İlaç San. ve Tic. A.Ş., Türkiye), 12 drops once daily (2 × 10⁹ CFU/day). Both probiotics were administered for two months. All children, including those in the control group, received an individualized, age- and weight-appropriate fiber-rich diet plan together with advice on age-appropriate fluid intake. No laxatives or other pharmacological treatments for constipation were given.

Assessments: Weekly defecation frequency (caregiver stool diary), stool consistency (modified Bristol Stool Form Scale for children), painful defecation and abdominal distension were recorded at baseline and at months 1 and 2. Adherence to the probiotic and dietary recommendations was assessed by caregiver report at each follow-up visit.

Outcomes: The primary outcomes were weekly defecation frequency and the presence of painful defecation at month 2. Secondary outcomes were weekly defecation frequency at month 1, stool consistency at months 1 and 2, painful defecation at month 1 and abdominal distension at months 1 and 2.

研究类型

介入性

注册 (实际的)

154

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Istanbul、土耳其(türkiye)、34295
        • Department of Pediatrics, Faculty of Medicine, Biruni University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 4年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 12 to 48 months
  • Functional constipation according to the Rome IV criteria for infants and toddlers (criterion G7): at least two of the following for at least one month: two or fewer defecations per week; history of excessive stool retention; history of painful or hard bowel movements; history of large-diameter stools; presence of a large fecal mass in the rectum. In toilet-trained children, at least one episode per week of incontinence after the acquisition of toileting skills and a history of large-diameter stools that may obstruct the toilet were also considered.
  • Written informed consent from a parent or legal guardian

Exclusion Criteria:

  • Organic cause of constipation (Hirschsprung disease, anorectal malformation, hypothyroidism, celiac disease, or a spinal or neuromuscular disorder)
  • Developmental delay
  • Previous gastrointestinal surgery
  • Use of probiotics, laxatives or antibiotics within the preceding 8 weeks

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Bacillus clausii + dietary management

Bacillus clausii oral suspension, 2 × 10⁹ spores (one 5-mL vial) once daily for 2 months, in addition to individualized dietary management.

Oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial; one vial once daily for 2 months.

其他名称:
  • 肠胚门

Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake.

实验性的:Lactobacillus rhamnosus GG + dietary management

Lactobacillus rhamnosus GG oral drops, 2 × 10⁹ CFU (12 drops) once daily for 2 months, in addition to individualized dietary management.

Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake.

Oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops; 12 drops once daily (2 × 10⁹ CFU/day) for 2 months.

其他名称:
  • Maflor
有源比较器:Dietary management alone

Individualized dietary management without a probiotic. Consecutive eligible children presenting during the same period; not randomized.

Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Weekly defecation frequency
大体时间:2 months after the start of treatment

Number of bowel movements per week, recorded from a stool diary kept by the caregiver.

2 months after the start of treatment
Proportion of children with painful defecation
大体时间:2 months after the start of treatment

Presence or absence of painful defecation, based on caregiver report at the follow-up visit

2 months after the start of treatment

次要结果测量

结果测量
措施说明
大体时间
Weekly defecation frequency
大体时间:1 month after the start of treatment

Number of bowel movements per week, recorded from a stool diary kept by the caregiver.

1 month after the start of treatment
Stool consistency (modified Bristol Stool Form Scale for children)
大体时间:1 month and 2 months after the start of treatment

Caregiver-rated stool form using the modified Bristol Stool Form Scale for children; higher scores indicate softer stools.

1 month and 2 months after the start of treatment
Proportion of children with painful defecation
大体时间:1 month after the start of treatment

Presence or absence of painful defecation, based on caregiver report at the follow-up visit.

1 month after the start of treatment
Proportion of children with abdominal distension
大体时间:1 month and 2 months after the start of treatment

Presence or absence of abdominal distension, assessed at the follow-up visit.

1 month and 2 months after the start of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:ABDULLAH SERT、Department of Pediatrics, Faculty of Medicine, Biruni University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年2月2日

初级完成 (实际的)

2021年7月1日

研究完成 (实际的)

2021年7月20日

研究注册日期

首次提交

2026年11月16日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • KAEK-151-2019
  • Ethics decision 151/2019 (其他标识符:Taksim Training and Research Hospital Clinical Research Ethics Committee)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data underlying the reported results will be available from the corresponding author upon reasonable request.

IPD 共享时间框架

Beginning after publication of the article, with no planned end date.

IPD 共享访问标准

De-identified individual participant data underlying the reported results will be available to researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author (asert@biruni.edu.tr); data will be shared after approval of the request and a data-sharing agreement.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅